Plasmapheresis for rheumatic diseases in the twenty-first century: Take it or leave it?

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 197-204

  Braun Moscovici, Yolanda ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; STAPHYLOCOCCUS PROTEIN A;

ALLERGIC REACTION; ANAPHYLAXIS; ARTHRALGIA; BIOSAFETY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATOMYOSITIS; DOUBLE BLIND PROCEDURE; FATIGUE; HEATING; HEMODYNAMICS; HEMOLYSIS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KINETICS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUROLOGIC DISEASE; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VASCULITIS;

ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 0038746803     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00005     Document Type: Review

References (102)

1. Abel JJ, Rowntree LG, Turner BB: On the removal of diffusable substances from the circulating blood of living animals by dialysis. J Pharmacol Exp Ther 1914, 5:275-316.
2. Campion EW: Desperate diseases and plasmapheresis. N Engl J Med 1992, 326:1425-1427.
3. Harada T, Myazaki M, Ozono Y, et al.: Therapeutic apheresis for renal diseases (editorial). Ther Apher 1998, 2:193-198.
4. Soltesz P, Aleksza M, Antal-Szalmas P, et al.: Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity 2002, 35(1):51-56. An interesting study regarding a possible influence of plasmapheresis on Th1/Th2 subsets in SLE.
5. Lewis EJ: Plasmapheresis in collagen vascular diseases. Ther Apher 1999, 3:172-177.
6. Sarode R, Gottschall JL, Aster RH, et al.: Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 1997, 54:102-107.
7. Gaskin G, Pusey CD: Plasmapheresis in antineutrophil cytoplasmic antibodies-associated systemic vasculitis. Ther Apher 2001, 5:176-181. A good review on plasmapheresis in ANCA-associated systemic vasculitis.
8. Cherin P, Auperin I, Bussel A, et al.: Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol 1995, 13:270-271.
9. Dau PC: Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol 1981, 38:544-552.
10. Shulman ST, Inocencio J, Hirsch R: Kawasaki disease. Pediatr Clin North Am 1995, 42:1205-1222.
11. Tizard JE: Recognition and management of Kawasaki disease. Curr Paediatr 1999, 8:97-101.
12. Freeman AF, Shulman ST. Recent developments in Kawasaki disease. Curr Opin Infect Dis 2001, 14:357-361. A very good review which discusses the recent developments and controversies in Kawasaki disease.
13. Villain E, Kachaner J, Sidi D, et al.: Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins. Arch Fr Pediatr 1987, 44(2):79-83.
14. Mori M, Tomono N, Yokota S: Coronary arteritis of Kawasaki Disease unresponsive to high dose intravenous gammaglobulin successfully treated with plasmapheresis. Nikon Rinsho Meneki Gakkai Kaishi 1995, 18:282-288.
15. Jaffe IA: Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann Rheum Dis 1963, 22:71-76.
16. Wallace DJ, Goldfinger D, Gatti R, et al.: Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Arthritis Rheum 1979, 22:703-710.
17. Wallace DJ, Goldfinger D, Lowe C, et al.: A double-blind controlled study of lymphoplasmapheresis versus sham apheresis for rheumatoid arthritis. N Engl J Med 1982, 1406-1410.
18. Wallace DJ, Klinenberg JR: Apheresis. Dis Monday 1984, 30(9):1-44.
19. Wallace DJ: How prosorba apheresis came to be used for rheumatoid arthritis: a personal historical perspective. Ther Apher 2001, 5(2):76-78. A review about the evolvement of apheresis, based on the personal experience of the author.
20. Rothwell RS, Davis P, Gordon PA, et al.: A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum 1980, 23:785-790.
21. Felson DT, LaValley MP, Baldassare AR, et al.: The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999, 42(10):2153-2159.
22. Langone JJ: Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by Streptococci and Pneumonococci. Adv Immunol 1982, 32:157-252.
23. Snyder HW, Balint JP, Jones FR: Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA columns. Semin Hematol 1989 (suppl 26) 1:31-41.
24. Wiesenhutter CW, Irish BL, Bertram JH: Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot study. J Rheumatol 1994, 21:804-812.
25. Caldwell J, Gendreau RM, Furst D: A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis. J Rheumatol 1999, 26(8):1657-1662.
26. Gendreau RM: A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 2001, 5(2):80-83. An interesting article that summarizes the pivotal clinical trial study concerning the safety and efficacy of the Prosorba column as a treatment of rheumatoid arthritis.
27. Simon JA, Lazo-Langner A, Duarte-Rojo A, et al.: Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjögren's syndrome. J Clin Apheresis 2002, 17(1):44-46. A case report about the use of plasmapheresis in a Sjögren patient with hyperviscosity syndrome.
28. Chen WH, Yeh JH, Chiu HC: Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren's syndrome. Eur Neurol 2001, 45(4):270-274. An interesting case report regarding the use of plasmapheresis in Sjögren-associated neuropathy.
29. Yamanouchi J, Yokota E, Yamauchi Y, et al.: A case of Sjögren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy. Ryumachi 1998, 38(4):595-599.
30. Feist E, Dorner T, Wagenmann A, Chaoui R, et al.: Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone. Z Rheumatol 1996, 55:127-132.
31. Gerraty RP, McKelvie PA, Byrne E: Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993, 88:309-311.
32. Van Eer MY, Netten PM, Schrijver G, et al.: Sjögren's syndrome complicated by cryoglobulinemia and acute renal failure. Neth J Med 1991, 39:23-27.
33. Thenint JP, Penniello MJ, Chapon F, et al.: Peripheral neuropathy in severe mixed cryoglobulinemia syndrome. Can J Neurol Sci 1987, 14:581-585.
34. Vasil'ev VI, Solov'ev SK, Chiklikchi AS, et al.: A positive effect of combined therapy (plasmapheresis in combination with pulse therapy) on the course of cryoglobulinemic glomerulonephritis and ulcerative-necrotic vasculitis in patients with Sjögren's disease. Ter Arkh 1987, 59:54-59.
35. Dau PC, Bennington JL: Plasmapheresis in childhood dermatomyositis. J Pediatr 1981, 98:237-240.
36. Herson S, Lok C, Roujeau JC, et al.: Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange. Ann Med Interne 1989, 140(6):453-455.
37. Miller FW, Leitman SF, Cronin ME, et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1386.
38. Clarke CR, Dyall-Smith DJ, Mackay IR, et al.: Plasma exchange in dermatomyositis/polymyositis: beneficial effects in three cases. J Clin Lab Immunol 1988, 27:149-152.
39. Lockwood CM, Rees AJ, Pinching AJ, et al.: Plasma-exchange and immunosuppression in the treatment of fulminant immune-complex crescentic nephritis. Lancet 1977, 1:63-67.
40. Guillevin L, Fain O, Lhote F, et al.: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective randomized trial in 78 patients. Arthritis Rheum 1992, 35:208-215.
41. Guillevin L, Lhote F, Cohen P, et al.: Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with poor prognostic factors. A prospective randomized trial in sixty-two patients. Arthritis Rheum 1995, 38:1638-1645.
42. Thysell H, Bygren P, Bengtsson U, et al.: Immunosuppression and the additive effect of plasma exchange in treatment of rapidly progressive glomerulonephritis. Acta Med Scand 1982, 212:107-114.
43. Glockner W, Sieberth HG, Wichmann HE, et al.: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled multi-center study. Clin Nephrol 1988, 29:1-88.
44. Cole E, Cattran D, Magil A, et al.: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kidney Dis 1992, 20:261-269.
45. Pusey CD, Rees AJ, Evans DJ, et al.: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991, 40:757-763.
46. Guillevin L, Cevallos R, Durand-Gasselin B, et al.: Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges: meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997, 148:198-204.
47. Hashimoto H, Yano T, Kawanashi T, et al.: Outcome of collagen vascular diseases by treatment with plasmapheresis. Ther Apher 1998, 2:268-272.
48. Lauque D, Cadranel J, Lazor R, et al.: Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 2000, 79:222-233. A study about the short- and long-term outcome of patients with vasculitis and alveolar hemorrhage and a comprehensive review of the literature.
49. Lamprecht P, Gause A, Gross WL: Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. Scand J Rheumatol 2000, 29:201-202. An interesting case report on hepatitis C virus associated cryoglobulinemic vasculitis, resistant to immunosuppressive therapy and responding to plasmapheresis.
50. Frasca GM, Zoumparidis NG, Borgnino LC, et al.: Combined treatment in Wegener's granulomatosis with crescentic glomerulonephritis Clinical course and long-term outcome. Int J Artif Organs 1993, 16(1): 11-19.
51. Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: what should be first-line therapy? Nephron 1994, 67:402-407.
52. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989, 9:368-375.
53. Andrassy K, Erb A, Koderisch J, et al.: Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991, 35:139-147.
54. Hogan SL, Nachman PH, Wilkman AS, et al.: Prognostic markers in patients with anti-neutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. JASN 1996, 7:23-32.
55. Bruns FJ, Adler S, Fraley DS, et al.: Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 1989, 86:400-406.
56. McLaughlin K, Jerimiah P, Fox JG, et al.: Has the prognosis for patients with pauci-immune necrotizing glomerulonephritis improved? Nephrol Dial Transplant 1998, 13:1696-1701.
57. Rasmussen N, Jayne DRW, Abramowicz D, et al.: European therapeutic trials in ANCA- associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995, 101(suppl 1):29-34.
58. Chen CL, Chiou YH, Wu CY, et al.: Cerebral vasculitis in Henoch-Schonlein purpura: a case report with sequential magnetic resonance imaging changes and treated with plasmapheresis alone. Pediatr Nephrol 2000, 15:276-278. A case report about cerebral vasculitis in a patient with Henoch-Schonlein purpura which improved after plasmapheresis.
59. Westman KW, Bygren PG, Olsson H, et al.: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998, 9:842-852.
60. Palmer A, Cairns T, Dische F, et al.: Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991, 6:536-542.
61. Matic G, Michelsen A, Hofmann D, et al.: Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher 2001, 5(1):68-72.
62. Stegmayr BG, Almroth G, Berlin G, et al.: Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int J Artif Organs 1999, 22:81-87.
63. Esnault VL, Testa A, Jayne DR, et al.: Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993, 65:180-184.
64. Jones JV, Cumming RH, Bucknall RC, et al.: Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976, 1:709-711.
65. Jones JV, Cumming RH, Bacon PA, et al.: Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979, 48:555-576.
66. Frank MM, Hamburger MI, Lawley TJ, et al.: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979, 300:518-523.
67. Lockwood CM, Worlledge S, Nicholas A, et al.: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979, 300:524-530.
68. Bonomini V, Vangelista A, Frasca GM, et al.: Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus. Clin Nephrol 1984, 22:121-126.
69. Blaszczyk M, Chorzelski T, Daszynski J, et al.: Plasmapheresis in the treatment of systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 1981, 29:769-772.
70. Lewis EJ: Plasmapheresis for the treatment of severe lupus nephritis: uncontrolled observations. Am J Kidney Dis 1982, 2:182-187.
71. Wallace DJ, Goldfinger D, Bluestone R, et al.: Plasmapheresis in lupus nephritis with nephrotic syndrome: a long-term followup. J Clin Apheresis 1982, 1:42-45.
72. Gipstein RM, Adams DA, Grabie MT, et al.: Response of lupus nephritis to plasmapheresis without demonstration of circulating immune complexes. Am J Med Sci 1982, 284:37-41.
73. Vangelista A, Frasca G, Orsi C, et al.: Short-term plasmapheresis in acute lupus nephritis. Int J Artif Organs 1983, (suppl)1:43-46.
74. Lewis EJ, Hunsicker LG, Lan SP, et al.: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992, 326:1373-1379.
75. Mistry-Burchardi N, Schonermarck U, Samtleben W: Apheresis in lupus nephritis. Ther Apher 2001, 5:161-170. A very good review on plasmapheresis in lupus nephritis.
76. Wallace DJ, Goldfinger D, Pepkowitz SH, et al.: Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 1998, 13:163-166.
77. Danieli MG, Palmieri C, Salvi A, et al.: Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apheresis 2002, 17:72-77. An important although open study, which showed that synchronized therapy of plasmapheresis and cyclophosphamide is not superior to conventional therapy at long term in proliferative lupus nephritis.
78. Erickson RW, Franklin WA, Emlen W: Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994, 24:114-123.
79. Isbister JP, Ralston M, Hayes JM, et al.: Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Successful management with plasmapheresis and immunosuppression. Arch Intern Med 1981, 141:1081-1083.
80. Koh WH, Thumboo J, Boey ML: Pulmonary hemorrhage in Oriental patients with systemic lupus erythematosus. Lupus 1997, 6:713-716.
81. Zamora MR, Warner ML, Tuder R, et al.: Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997, 76:192-202.
82. Santos-Ocampo AS, Mandell BF, Fessler BJ: Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000, 118:1083-1090. The authors describe the clinical course of 7 patients with SLE and alveolar hemorrhage and review the literature.
83. Schwab EP, Schumacher HR Jr., Freundlich B, et al.: Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993, 23:8-15.
84. Barile LA, Jara LJ, Medina-Rodriguez F, et al.: Pulmonary hemorrhage in systemic lupus erythematosus. Lupus 1997, 6:445-448.
85. Liu MF, Lee JH, Weng TH, et al.: Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 1998, 27:291-295.
86. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993-997.
87. Kobayashi S, Tamura N, Tsuda H, et al.: Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis 1992, 51:399-401.
88. Lockshin MD: Answers to the antiphospholipid-antibody syndrome? N Engl J Med 1995, 332:1025-1027.
89. Asherson RA, Piette JC: The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996, 5:414-417.
90. Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998, 77:195-207.
91. Jain R, Chartash E, Susin M, et al.: Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 1994, 24:173-182.
92. Nesher G, Hanna VE, Moore TL, et al.: Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994, 24:165-172.
93. Rock GA, Shumak KH, Buskard NA, et al.: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325:393-397.
94. Gelfand J, Truong L, Stern L, et al.: Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma infusion. Am J Kidney Dis 1985, 6:154-160.
95. Aster RH: Plasma therapy for thrombotic thrombocytopenic purpura. Sometimes it works, but why? N Engl J Med 1985, 312:985-987.
96. Stricker RB, Davis JA, Gershow J, et al.: Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J Rheumatol 1992, 19:1469-1473.
97. Fitchen JJ, Cline MJ, Saxon A, et al.: Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus. Recovery after exchange plasmapheresis. Am J Med 1979, 66:537-542.
98. Brooks BJ Jr., Broxmeyer HE, Bryan CF, et al.: Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 1984, 144:1474-1477.
99. Finkelstein Y, Adler Y, Harel L, et al.: Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. Ann Med Interne (Paris) 1997, 148:205-208.
100. Keller AJ, Chirnside A, Urbaniak SJ: Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels. Br J Haematol 1979, 42:593-603.
101. Sultan Y, Bussel A, Maisonneuve P, et al.: Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease. Transfusion 1979, 19:588-593.
102. Laskus T, Cianciara J, Slusarczyk J: Follow-up of NANB hepatitis outbreak in plasmapheresis unit. Lancet 1989, 1:391.